AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- A group B meningococcal N-propionylated polysaccharide conjugate vaccine was safe in adult, male volunteers, but did not appear to be efficacious.
According to recent research published in the journal Vaccine, "The safety and immunogenicity of a group B meningococcal vaccine, consisting of N-propionylated (NPr) B capsular polysaccharide conjugated to tetanus toxoid, was tested for the first time, in 17 healthy male volunteers aged between 18 and 40 years. Four escalating dosages of vaccine were tested and each was given as three intramuscular injections at 4-week intervals. The vaccine was well tolerated and induced only mild and transient, dose-dependent, injection-site reactions.
"One month after the last injection, there was no evidence of the production of auto-antibodies or antibodies binding to PSA-NCAM," reported Joelle Bruge and colleagues at Aventis Pasteur France. "The vaccine induced an increase in the pre-existing titers of IgM specific to B polysaccharide and NPr B polysaccharide. Moreover, it induced IgG antibodies specific to NPr B polysaccharide, which ...
Source: HighBeam Research, Group B meningococcal vaccine safe but not effective in men.